Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for axial spondyloarthritis:
- Tofacitinib for treating active ankylosing spondylitis (2023) NICE technology appraisal guidance 920
- Bimekizumab for treating axial spondyloarthritis (2023) NICE technology appraisal guidance 918
- Upadacitinib for treating active non-radiographic axial spondyloarthritis (2023) NICE technology appraisal guidance 861
- Upadacitinib for treating active ankylosing spondylitis (2022) NICE technology appraisal guidance 829
- Secukinumab for treating non-radiographic axial spondyloarthritis (2021) NICE technology appraisal guidance 719
- Ixekizumab for treating axial spondyloarthritis (2021) NICE technology appraisal guidance 718
This page was last updated: